Hachulla Eric, Carpentier Patrick, Gressin Virginie, Diot Elisabeth, Allanore Yannick, Sibilia Jean, Launay David, Mouthon Luc, Jego Patrick, Cabane Jean, de Groote Pascal, Chabrol Amélie, Lazareth Isabelle, Guillevin Loïc, Clerson Pierre, Humbert Marc
Department of Internal Medicine, National Reference Center for Scleroderma, Claude Huriez Hospital, University of Lille, 59037 Lille cedex, France.
Rheumatology (Oxford). 2009 Mar;48(3):304-8. doi: 10.1093/rheumatology/ken488. Epub 2009 Jan 27.
This longitudinal study investigated survival, risk factors and causes of death in the multicentre ItinérAIR-Sclérodermie cohort of patients with SSc without severe pulmonary fibrosis or severe left heart disease at baseline.
At 3-year follow-up, vital status was obtained from investigators or French national death records. Causes of death were classified as SSc-related or otherwise. Data were censored at 37 months, time of death or loss to follow-up, whichever was earlier. Survival was estimated using the Kaplan-Meier method. Multivariate survival analyses were conducted using the Cox model.
In total, 546 patients were followed for a median duration of 37 months, representing 1547 patient-years. At baseline, the majority of patients were female, with lcSSc, mean age 54.9 +/- 13.0 years and mean duration of SSc of 8.8 +/- 8.1 years. In total, 47 patients died, giving a 3-year survival of 91.1% and cumulative mortality of 3.04 deaths per 100 patient-years; 17 deaths (32.2%) resulted from pulmonary arterial hypertension (PAH) and eight (17.1%) from cancer. Of the 47 patients with PAH at baseline, 20 died during follow-up, giving a 3-year survival of 56.3%. In a multivariate analysis, PAH [hazard ratio (HR) 7.246], age at first symptom (HR 1.052), duration of SSc (HR 1.047 per year) and Rodnan skin score (per one point) (HR 1.045) were associated with increased mortality.
This 3-year study observed survival and mortality estimates that were comparable with previous reports. PAH increased the HR for mortality in patients with SSc, justifying yearly echocardiographic screening.
这项纵向研究调查了多中心ItinérAIR - 硬皮病队列中基线时无严重肺纤维化或严重左心疾病的系统性硬化症(SSc)患者的生存率、危险因素和死亡原因。
在3年随访时,从研究者处或法国国家死亡记录中获取生命状态。死亡原因分为与SSc相关或其他原因。数据在37个月、死亡时间或失访时间(以较早者为准)进行截尾。采用Kaplan - Meier方法估计生存率。使用Cox模型进行多变量生存分析。
总共对546例患者进行了中位时长为37个月的随访,相当于1547患者年。基线时,大多数患者为女性,患有局限性皮肤型系统性硬化症(lcSSc),平均年龄54.9±13.0岁,SSc平均病程8.8±8.1年。共有47例患者死亡,3年生存率为91.1%,累积死亡率为每100患者年3.04例死亡;17例死亡(32.·2%)由肺动脉高压(PAH)导致,8例(17.1%)由癌症导致。基线时患有PAH的47例患者中,20例在随访期间死亡,3年生存率为56.3%。在多变量分析中,PAH[风险比(HR)7.246]、首发症状时的年龄(HR 1.052)、SSc病程(每年HR 1.047)和罗德南皮肤评分(每增加1分)(HR 1.045)与死亡率增加相关。
这项为期3年的研究观察到的生存率和死亡率估计与先前报告相当。PAH增加了SSc患者的死亡风险比,证明每年进行超声心动图筛查是合理的。